Price movement over the last 24 hours
Asana Inc. vs FMC Corp — how do they compare? Asana Inc. trades at $7.36 (market cap $1.69B), while FMC Corp trades at $10.92 (market cap $1.37B). The key difference: Asana Inc. is the larger of the two by market cap, and FMC Corp pays a 2.93% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | FMC | |
|---|---|---|
Market Cap | $1.69B | $1.37B |
Sector | Consumer Cyclical | Basic Materials |
52-Week High | $15.35 | $43.90 |
52-Week Low | $5.46 | $10.80 |
Enterprise Value | $1.51B | $5.51B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
FMC Corporation (FMC) trades at $10.91, showing minimal daily movement with a 0.18% gain. The stock faces significant fundamental challenges, including a net loss of -$2.24 billion in 2025 and negative profit margins, though recent strategic moves like a $400 million investment from Tessenderlo Group and asset sales aim to reduce debt. Technical indicators are bearish, with the stock trading near key support levels. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings but a consensus price target of $17.00 suggesting substantial upside potential from current levels.
The outlook for FMC hinges on successful debt reduction and the commercial success of new products like rimisoxafen. While the current valuation metrics (P/S: 0.4, P/B: 0.75) appear attractive, the deeply negative profitability and high debt load present significant risks. The potential for a operational turnaround exists, but investors should weigh the high risk of continued losses against the possibility of a recovery driven by new technology and improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →